Clinical Trial Update: A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of ABBV-927 and ABBV-181 in participants with advanced solid tumors is active but not currently recruiting, with ongoing immunotherapy evaluation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• ABBV-181
• ABBV-927

Snippet

Sponsor: AbbVie | Conditions: Advanced Solid Tumors Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING